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Introduction
The risk of postthrombotic syndrome (PTS) development after acute deep vein thrombosis (DVT) is particularly high if the common femoral or the iliac veins are thrombosed [1] . With conservative management including anticoagulation and medical compression stockings, more than half of patients with an acute iliofemoral DVT (IFDVT) develop PTS [2] . Because PTS adversely affects health-related quality-of-life (QOL) in affected patients and is costly to society, prevention of PTS has become a major treatment goal in acute DVT management [3] .
The Norwegian Catheter-directed Venous Thrombolysis (CaVenT) trial has recently underlined the importance of the 'open vein hypothesis', which postulates that early thrombus removal prevents persistent venous obstruction and venous valve incompetence, the two main known pathophysiologic mechanisms for the development of PTS [2, 4, 5] . Patients with IFDVT treated with additional catheter-directed thrombolysis (CDT) had a clinical benefit in terms of absolute PTS risk reduction of 15% after 2 years and 28% after 5 years compared with patients treated with anticoagulation therapy alone [2, 4] . Iliofemoral patency and femoro-popliteal venous valve incompetence assessed by duplex sonography at 6 months were the strongest predictors of PTS development [5] , underlining the importance of duplex sonographic assessment during follow-up to identify patients at risk of PTS [6] .
A further step in the development of CDT was ultrasound-assisted CDT (USAT), which combines CDT with a catheter system that applies high-frequency, low-power ultrasound energy within the thrombus [7] . Initial reports of retrospective studies suggested better thrombus removal, shorter treatment times and lower bleeding complication rates with USAT compared with standard CDT [8, 9] . In contrast to these non-randomized studies, the BERN Ultrasound-assisted Thrombolysis for Ilio-Femoral deep vein thrombosis versUs standard catheter directed thromboLysis (BERNUTIFUL) randomized, controlled, core laboratory adjudicated trial with direct comparison between USAT and CDT for the treatment of IFDVT, found no significant enhanced thrombus resolution with USAT using a fixeddose catheter thrombolysis regimen (20 mg r-tPA over 15 hours) [10] .
The aim of the present study was to assess the impact of adding intravascular high-frequency, low-power ultrasound energy during CDT on 12-month clinical and duplex sonographic outcomes, including PTS and venous disease severity, disease-specific QOL, venous patency and reflux.
Methods

Patients and study design
The BERNUTIFUL trial was designed as a single-center, open-label, randomized-controlled, core laboratory adjudicated, clinical trial to evaluate whether the addition of intravascular high-frequency, low-power ultrasound increases the efficacy of standardized CDT in reducing the thrombus load in patients with an acute IFDVT. Patients aged 18-75 years with symptomatic proximal DVT involving the iliac or common femoral veins with symptom duration of ≤ 14 days and objectively confirmed by duplex sonography were included. Complete inclusion and exclusion criteria have been published elsewhere [10] . Written informed consent was obtained from all patients. The study protocol was approved by the local ethics committee and is registered at ClinicalTrials.gov, NCT01482273.
Randomization and masking
Included patients were randomly allocated in a 1 to 1 ratio to either a fixed-dose ultrasound-assisted CDT (USAT group) or a fixed-dose conventional CDT (CDT group = control group) according to a simple randomization sequence without stratification using random block sizes of four and six created with Stata statistical software (StataCorp, College Station, TX, USA) [11] . Consecutively numbered, sealed envelopes containing the group allocation were stored at the Venous Thromboembolism Research Group office, accessible only to the principal and co-investigators and dedicated study nurses.
The BERNUTIFUL trial was open-label, except for the primary outcome measure (the percentage of thrombus load reduction from baseline to 15 h of CDT according to the length-adjusted thrombus [LAT] score [10] ), assessed by an independent core laboratory (coreLab, Bad Krozingen GmbH, Bad Krozingen, Germany) that was masked to group assignment. The assessors of the 12-month outcomes were not masked to group assignment.
Procedures
Anticoagulation with a bolus of unfractionated heparin (UFH, 80 units per kg bodyweight) followed by continuous intravenous UFH infusion at a therapeutic dose range (equivalent to 0.3-0.7 IU mL À1 by factor Xa inhibition) was started immediately after confirmation of IFDVT diagnosis [10] . During CDT, UFH infusion was administered through the venous access sheath and adjusted every 6 h in order to maintain therapeutic dose levels. After CDT, switch from UFH to low-molecularweight heparin (LMWH), fondaparinux or rivaroxaban, or the initiation of vitamin K antagonist, was allowed after a minimum duration of 24 h UFH infusion. Type and duration of anticoagulation therapy after CDT were according to the decision of the treating vascular specialist [12] . Details on the CDT procedure have been published previously [10] . With the patient in the prone position, venous access with a 7-French introducer sheath was obtained under ultrasound guidance at the popliteal vein of the affected leg, regardless of whether it was thrombosed or patent. In the case of isolated iliac vein thrombosis, venous access was obtained at the common femoral vein, with the patient in the supine position. In both study groups, the EkoSonic MACH4 Endovascular System catheter (EKOS Corporation, Bothell, WA, USA) was used with a standardized catheter thrombolysis protocol of 20 mg recombinant tissue plasminogen activator (r-tPA; Actilyse extension. The rate was 2 mg h À1 for the first 5 h, then reduced to 1 mg h À1 for the remaining 10 h [13] . 
Outcomes
We have previously reported on the primary outcome measure of the BERNUTIFUL trial: the percentage of thrombus load reduction from baseline to 15 h of CDT according to the length-adjusted thrombus (LAT) score, and the clinical outcomes at 3-month follow-up [10] . In the present study we report on the predefined clinical and duplex sonographic outcomes at 1-year follow-up. The clinical follow-up visit at 1 year included a standardized clinical examination and duplex ultrasound study performed by experienced vascular specialists after a specific training period [10] . The presence and severity of the PTS were assessed using the Villalta score, consisting of five patient-rated leg symptoms (pain, cramps, heaviness, paresthesia and pruritus) and six physicianrated clinical signs (pretibial edema, skin induration, hyperpigmentation, redness, venous ectasia and pain on calf compression) [14, 15] . For each item, a score of 0 (none) to 3 (severe) points was given and points were summed into a total score (range 0-33). Absence of PTS was defined by a total score of < 5 points. PTS was classified as mild (total score 5-9 points), moderate (10-14 points) or severe (≥ 15 points or presence of a venous ulcer) [14, 15] . We also assessed the presence and severity of chronic venous disease using the Clinical Etiological Anatomical Pathophysiological (CEAP) classification [16] and the revised venous clinical severity score (rVCSS) [17] . Disease-specific QOL was assessed using the German version of the Chronic Venous Insufficiency Questionnaire (CIVIQ-20), evaluating four domains (physical, psychological, social and pain) with a total of 20 questions (scored with 1-5 points), with a recall period of the previous week. Total CIVIQ-20 scores range from 20 (excellent QOL) to 100 points (terrible QOL) [18] .
Duplex ultrasound studies were performed using a Siemens S2000 (Siemens AG, Medical Solutions, Zurich, Switzerland), with a broad-spectrum linear array transducer (9L4; frequency range, 4-9 MHz) for femoral and popliteal veins and a curved array transducer (4C1; frequency range, 1-4.5 MHz) for pelvic veins. Greyscale compression ultrasonography was used for the detection of postthrombotic vein lesions (incompressibility, wall thickening and intraluminal hyperechoic structures) in the femoral and popliteal veins. Residual vein thrombosis was considered present if any segment from the common femoral to the popliteal veins had a diameter during compression of ≥ 40% of vein diameter before compression [19] . Color-coded duplex sonography was used to assess the patency of each vein segment from the popliteal to the common iliac vein, defined as spontaneous orthograde venous flow, and to evaluate venous flow variation with respiration. Venous incompetence was assessed with the patient in an upright position and the weight taken on the opposite limb using a Valsalva maneuver for the common femoral vein and manual compression/release for the femoral and popliteal veins [20] . Venous reflux was defined as valve closure time of ≥ 1 s [20] .
The primary iliofemoral patency rate was defined as the percentage of patients with primary treatment success and without the occurrence of either thrombosis of the treated iliofemoral vein segment or a re-intervention to maintain patency of the treated segment [13, 21] . The secondary iliofemoral patency rate was defined as the percentage of patients with primary treatment success and without permanent loss of flow in the treated iliofemoral segment, irrespective of any interval therapies [21] . Safety endpoints were the incidence of bleeding complications according to the International Society on Thrombosis and Haemostasis [22] , and the recurrence of thromboembolic complications during follow-up.
Statistical analysis
Clinically relevant outcomes (QOL, PTS, rVCSS, CEAP class, bleeding complications and recurrent venous thromboembolic events) at 12 months were among the prespecified secondary outcomes of the BERNUTIFUL trial, whereas the sample size calculations were based on the primary outcome of mean percentage of thrombus load reduction from baseline to 15 h of catheter thrombolysis according to the length-adjusted thrombus score [10] . Data are presented as means AE standard deviations or range of values for continuous variables, and as absolute numbers and percentages with 95% confidence intervals (CIs) where appropriate for categorical variables. Comparisons between the two study groups were performed using the unpaired t-test or Wilcoxon rank-sum test where appropriate for continuous variables and Fisher's exact test for categorical variables. Comparisons of repeated measurements at 3 and 12-month follow-up visits within a study group were performed using the paired t-test or Wilcoxon signed-rank test for continuous variables and the McNemar test for categorical variables. Study outcomes were analyzed according to the intentionto-treat principle [11] . Primary and secondary iliofemoral patency rates were calculated using the Kaplan-Meier survival analysis. Baseline characteristics (age, gender, obesity, presence or personal history of varicose veins, previous DVT, provoked/unprovoked DVT), treatment group, absolute thrombus load before and after thrombolysis according to the LAT score and percentage of thrombus load reduction, presence of stent and duplex sonographic outcomes at 12 months were considered as possible predictors of total Villalta PTS score at 12 months in univariate linear regression analysis [3, 23] . All statistical analyses were performed using STATA version 14.1 (StataCorp, College Station, TX, USA) and P-values < 0.05 were considered as statistically significant.
Results
Between 25 November 2011 and 27 October 2013 we enrolled and randomized a total of 48 patients. During the 12-month follow-up period, three (6.3%; 95% CI, 1.3-17.2%) patients died as a result of advanced metastatic cancer, two (8.3%) in the CDT group and one (4.2%) in the USAT group (P = 0.55), after a mean follow-up of 267 (range, 224-335) days. Baseline characteristics, including thrombus extension (Table 1) , interventional therapy and anticoagulation therapy (Table 2) , of the remaining 45 (93.8%) patients with follow-up data at 12 month were similar in both groups.
Postthrombotic syndrome, venous clinical severity score and CEAP classification Mean total Villalta score at 12-month follow-up was 2.0 AE 2.4 points (range, 0-11), without any difference between the USAT and the CDT groups (Table 3) , and similar to the mean score at 3 months follow-up (2.5 AE 3.0 [range, 0-15]; P = 0.32).
Overall, 40 (88.9%; 95% CI, 75.9-96.3%) patients were free from PTS according to the Villalta score at 12 months follow-up, with no difference between the USAT (82.6%; 95% CI, 61.2-95.0%) and the CDT groups (95.5%; 95% CI, 77.2-99.9%; P = 0.17). A total of four (8.9%; 95% CI, 2.5-21.2%) patients had a mild PTS, and one (2.2%; 95% CI, 0.1-11.8%) patient had a moderate PTS (Table 3 ). The latter patient from the USAT group had preexisting primary chronic venous disease with an estimated total Villalta score of 8 points before study inclusion. Total Villalta score at 12 months was significantly higher in patients with a personal history of lower extremity DVT as compared with patients with first-time DVT (4.2 AE 3.3 vs. 1.5 AE 1.8 points; P = 0.001). Total Villalta score at 12 months was also higher in patients with varicose veins at baseline as compared with patients without varicose veins (4.5 AE 3.0 vs. 1.2 AE 1.5 points; P < 0.001).
In univariate linear regression analysis, the following baseline characteristics showed a significant association with total Villalta score at 12 months: age (P = 0.021), presence of varicose veins (P < 0.001) and prior DVT (P = 0.001). Neither any of the procedural data nor the sonographic parameters were associated with the total Villalta score at 12 months.
Total mean revised venous clinical severity score at 12 months was 2.7 AE 2.9 (range, 0-12) points in the whole study group, with no difference between the USAT and the CDT groups (Table 3) , and significantly lower than at 3 months follow-up (3.6 AE 2.6; P = 0.02). This decrease was mainly explained by the reduced usage of compression stockings (1.9 AE 1.3 points at 3 months vs. 1.2 AE 1.3 points at 12 months; P = 0.002). The percentage of patients with full compliance with medical compression stockings (wearing stockings every day) significantly decreased from 53.3% at 3 months to 24.4% at 12 months follow-up (P = 0.002) and was similar for both the USAT (50.0% vs. 21.7%) and the CDT (56.5% vs. 27.2%) groups. The percentage of patients with no medical compression stockings increased from 24.4% at 3 months to 44.4% at 12 months follow-up (P = 0.02), without any difference between the USAT (from 31.8% to 43.5%) and the CDT (from 17.4% to 45.4%) groups.
CEAP class distribution was similar between the study groups (P = 0.45; Table 3 ). Of note, patients with clinical class C4b and C5 at 12 months already had these clinical signs before study inclusion as a result of primary chronic venous disease.
Disease-specific quality of life Disease-specific QOL was good in both groups, with a total CIVIQ-20 score at 12 months follow-up of 27.9 AE 10.2 points in the whole study group, without any difference between the USAT (29.4 AE 11.8 points) and the CDT (26.1 AE 7.8 points; P = 0.30) groups. Total CIVIQ-20 score at 12 months was similar to the total score at 3 months follow-up (27.7 AE 10.1; P = 0.97), but significantly lower than at baseline (54.5 AE 15.6 points; P < 0.001), with a similar total CIVIQ-20 score improvement from baseline to 12 months in both study groups (À29.5 AE 14.8 and À18.4 AE 20.5 points in the USAT and CDT groups, respectively; P = 0.08). None of the duplex sonographic parameters assessed at 12 months was a significant predictor for the total CIVIQ-20 score at 12 months (reflux in popliteal veins with lowest P-value at 0.09). Total Villalta score was not associated with total CIVIQ-20 score (P = 0.44).
Venous thromboembolic and bleeding complications during follow-up
Venous thromboembolic events occurred in five (10.4%; 95% CI 3.5-22.7%) patients, two (8.3%; 95% CI, 1.0-27.0%) in the CDT group and three (12.5%; 95% CI, 2.7-32.4%) in the USAT group (P = 0.64). In the CDT group, one patient initially treated with extensive stenting from the proximal femoral vein up to the external iliac vein had an early re-thrombosis at day one, which was successfully treated with USAT, but the external iliac and femoral veins were reoccluded at the 3-month follow-up visit; one patient had a late re-thrombosis at day 183, successfully treated with USAT and stent placement. In the USAT group, two patients were diagnosed with a low-risk pulmonary embolism at day 34 and day 104, respectively, and one patient had an asymptomatic DVT at another venous site diagnosed at the 6-month follow-up visit. No bleeding complication was noted during follow-up. (51) 12 (52) 11 (50) 3 months 12 (27) 7 (30) 5 (23) 6 months 6 (13) 3 (13) 3 (14) 12 months 5 (11) 2 (9) 3 (14) Extended duration 22 (49) 11 (48) 11 (50) Data presented as mean AE SD or number (%). *Angioplasty without stenting was not performed. CDT, catheter-directed thrombolysis; LMWH, low-molecular-weight heparin; r-tPA, recombinant tissue plasminogen activator; USAT, ultrasound-assisted catheter-directed thrombolysis. 
Patency rates and duplex sonographic outcomes
Primary and secondary iliofemoral patency rates for the whole study group at 12 months follow-up were 95.7% (95% CI, 83.9-98.9%) and 97.8% (95% CI, 85.6-99.7%), respectively. There was no difference in primary (100% vs. 91.7%; P = 0.39) or secondary (100% vs 95.8%; P > 0.99) iliofemoral patency rates between the USAT and the CDT groups. All duplex ultrasound parameters assessed at 12 months follow-up were similar between the USAT and the CDT groups (Table 4) . Postthrombotic vein lesions in the femoro-popliteal veins were detected in 18 (40%) patients, without any difference between the USAT (10, 43.5%) and the CDT groups (8, 36.4%; P = 0.43). Residual vein thrombosis in the femoro-popliteal veins was present in five (11.1%) patients, without any difference between the USAT (1, 4.4%) and the CDT groups (4, 18.2%; P = 0.16). Femoro-popliteal venous reflux was detected in 16 (36.4%) patients, with nine (39.1%) patients in the USAT group and seven (33.3%) in the CDT group (P = 0.76).
Discussion
Follow-up results from the randomized, controlled BER-NUTIFUL trial, treating patients with acute IFDVT according to a standardized fixed dose catheter thrombolysis regimen, show that clinical outcomes are favorable at 1 year, with a low incidence of PTS and good disease-specific QOL, irrespective of the addition of intravascular high-frequency, low-power ultrasound energy. Furthermore, duplex sonographic vein assessment showed a very high patency rate with a low incidence of valve incompetence, suggesting that these patients have a high likelihood of remaining free of PTS in the future. Catheter-based thrombus removal therapy is currently suggested as first-line therapy for prevention of the PTS in selected patients with IFDVT [3] . Nevertheless, the availability of robust high-quality data from randomized trials is limited. The CaVenT study proved the superiority of CDT in the prevention of PTS, but still demonstrated a relatively high PTS rate of 41% (vs. 56% with standard conservative treatment) at 2 years, with similar rates after 5 years follow-up (43% vs. 71%, respectively) [2, 4] . In contrast, only 11% of patients developed a PTS at the end of follow-up in the BERNUTIFUL study. This more than relevant difference in the incidence of PTS cannot be explained by the addition of intravascular ultrasound energy compared with standard CDT in the CaVenT study, because in the BERNUTIFUL study we did not observe any difference between CDT and USAT. The higher stenting rate of 80% (vs 17% in the CaVenT study) is likely to play an important role with regard to the low rate of PTS in BERNUTIFUL [2, 10, 13] . Immediate adjunctive stent placement after catheter-based therapy for acute IFDVT has been shown to improve iliofemoral patency [24, 25] , and the latter is significantly associated with reduced PTS risk in the CaVenT study [2] . In contrast to the CaVenT study with less than half of the patients having thrombus extension to the iliac veins, nearly all of the patients included in the BERNU-TIFUL study had a thrombotic occlusion of iliac veins, whereas the popliteal veins were thrombosed in only onethird of patients. This suggests that most of the patients enrolled in the present study were suffering from a descending IFDVT where venous outflow obstruction (e.g. May-Thurner syndrome) is certainly one of the main pathophysiological factors [26] , whereas inflow from the lower leg veins is likely to be good, explaining the high patency rate of the popliteal vein after catheter-thrombolysis. To maintain patency after thrombolysis and to prevent recurrent thrombotic occlusions and venous hypertension, this underlying outflow obstruction needs to be treated with routine venous stenting [13] . The overall favorable clinical results with a low incidence of PTS in our study are certainly encouraging, but the study design with absence of a conservative control group does not allow firm conclusions on the utility of the catheterbased therapy. Venous stenting after IFDVT is probably still underused and further research is needed to clearly define the role of stenting in this setting.
In the BERNUTIFUL study, age and personal history of varicose veins or of DVT were the only factors associated with an increased total Villalta score at 12 months [3] . This is not surprising because preexisting venous disease burden is higher in these patients and is unlikely to improve after successful treatment of IFDVT. Furthermore, the recommended Villalta score for the diagnosis of PTS is not specific and does not account for preexisting venous disease. Of note, history of DVT was one of the main predictors of clinical deterioration in patients with varicose veins in the large population-based 'Edinburgh Vein Study' [27] . Previous studies consistently reported worse QOL scores in patients with PTS than in those without [28, 29] . However, the CaVenT study did not find any difference in generic and disease-specific QOL between patients treated with additional CDT and those with conservative management, possibly explained by the diagnostic properties of QOL assessment and the frequency of PTS [4, 29] . Our study shows a good disease-specific QOL in both study groups at the end of follow-up, with a significant improvement after baseline values. Unfortunately, a direct comparison with the results from the CaVenT study is impossible because different QOL questionnaires were used [29] . In contrast to the study by Broholm et al., who reported better QOL scores in patients with patent veins and sufficient valves after additional CDT [28] , we did not observe any association between any of the duplex sonographic parameters and QOL scores, possibly because of the high patency rates.
The influence of intravascular ultrasound energy on the venous wall and valvular function has not yet been studied. Theoretically, ultrasound energy applied during several hours might cause vein wall and valvular damage through heat production and acoustic cavitation [30, 31] . Because initial thrombolytic effect and residual thrombus load after catheter thrombolysis were the same in the CDT and the USAT groups [10] , we assumed that any difference in duplex sonographic outcomes during follow-up would arise from the application of intravascular ultrasound energy. Such adverse effects related to ultrasound energy seem to be unlikely because we didn't observe any difference in patency, valvular reflux or postthrombotic vein lesions between the two study groups. Our results question the added value of the increased costs for the USAT catheter system, at least in the setting of acute IFDVT.
Besides patency, the preservation of venous valve function is of importance to avoid venous hypertension and PTS [5] . We detected femoro-popliteal venous reflux in only one-third of patients, whereas 65% of CDT patients (vs. 77% in the conservative management group) in the CaVenT study had femoro-popliteal reflux after 6 months, with similar rates after 2 and 5 years follow-up [4, 5] . In contrast, Baekgaard et al. found patent veins without reflux in 82% of limbs treated with CDT (venous stenting in 55%) after 6 years follow-up [6] . However, they excluded patients with popliteal vein thrombosis in the latter study, which could have favorably influenced their results. Interestingly, a recent study found that onethird of patients diagnosed with DVT had deep vein reflux in the contralateral leg, whereas only 13% in the control group of patients with suspected DVT had deep vein reflux [32] , suggesting that preexisting reflux is an important risk factor for DVT and likely to contribute to postthrombotic morbidity [32, 33] . As patients without deep vein reflux are unlikely to develop a PTS, duplex sonographic assessment of deep vein reflux remains a valid endpoint in future studies [5] .
Our study has several limitations. The 12-month follow-up for the assessment of PTS is relatively short in comparison to similar studies [2, 4, 6] , knowing that symptoms and signs of PTS might develop several years after the initial DVT. However, in line with our data, Kahn et al. found that the Villalta score 1 month after DVT diagnosis was highly predictive of Villalta scores over 2 years of follow-up, suggesting that the pathophysiologic progenitor of PTS occurs during the initial few weeks after DVT diagnosis [1] . The CIVIQ score has only been validated for the disease-specific QOL assessment in the setting of chronic venous disease, rather than in the acute setting of DVT [18] . Finally, our sample size was relatively small and the study was not powered for the presented secondary outcomes. We cannot rule out a type II statistical error and that a larger sample size would have been more adequate to detect smaller differences between the two study groups. However, because of the identical thrombus load reduction in both study groups as primary outcome, we believe that this is rather unlikely [10] .
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